Qimin Chao

This inventor holds 5 USPTO granted patents and 1 published patent application, plus 3 CIPO patents and 3 EPO patents. Top assignee: Morphotek, Inc.. Active years: 2010-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Qimin Chao. Retrieved from https://idiyas.com/inventor/qimin-chao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 5 (Patent Applications = 1)

% Patents Active = 100.0

CIPO Patents = 3

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 7.0

ph-index = 3

Forward Citations = 45(Granted Patents)

Company Filing History:

5 out of 65

Morphotek, Inc.

patents

Years Active: 2010-2018

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10023632 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2018-07-17),

2. 9422367 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2016-08-23),

3. 8623364 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2014-01-07),

4. 8318168 - Antigenic GM-CSF peptides and antibodies to GM-CSF (2012-11-27),

5. 7741450 - Antibodies to GM-CSF (2010-06-22),

Title: Qimin Chao: Innovator in Antibody Development

Introduction

Qimin Chao is a notable inventor based in Havertown, PA (US), recognized for his contributions to the field of biotechnology. He holds a total of five patents, showcasing his innovative approach to developing therapeutic methods.

Latest Patents

Among his latest patents are significant advancements in antigenic GM-CSF peptides and antibodies to GM-CSF. These patents detail hybridoma lines that secrete human monoclonal antibodies with high binding specificity and biological activity. Notably, these antibodies exhibit neutralizing activity against granulocyte-macrophage colony-stimulating factor. The methods of generating these hybridoma lines are also provided, along with target antigens and epitopes. The applications of these antibodies extend to therapeutic methods, particularly in the treatment of cancer, infectious diseases, and autoimmune diseases.

Career Highlights

Qimin Chao has worked with prominent companies in the biotechnology sector, including Morphotek, Inc. and Eisai Inc. His work in these organizations has contributed to the advancement of therapeutic antibody development.

Collaborations

Some of his notable coworkers include Philip M. Sass and Nicholas C. Nicolaides, who have collaborated with him on various projects in the field.

Conclusion

Qimin Chao's innovative work in antibody development has significant implications for therapeutic applications. His contributions continue to influence the biotechnology landscape, particularly in the treatment of critical health conditions.

Profile summary based on public USPTO records.